ALSO NOTED: Osiris files IPO; Amgen initiates kidney disease study; and much more...

> Baltimore-based stem cell therapeutic company Osiris Therapeutics announced an IPO at 3.5 million shares for about $11 to $13 each. Report

> Chutes & Ladders: Ann, Arbor, MI-based Aastrom Biosciences has named George W. Dunbar CEO and president. Release

> Melbourne-based CSL Limited will acquire biotech Zenyth Therapeutics for about $108 million. Release

> Amgen is initiating a 3,800-person study of Sensipar/Mimpara for kidney disease. Report

And Finally... The Senate will continue to debate three stem cell bills which President Bush has pledged to veto if passed. Article (WSJ sub. req.)

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.